Jpmorgan Chase & CO Macrogenics Inc Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Macrogenics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 745,062 shares of MGNX stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
745,062
Previous 546,807 36.26%
Holding current value
$1.18 Million
Previous $1.78 Million 46.76%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$1.26 - $3.49 $249,801 - $691,909
198,255 Added 36.26%
745,062 $946,000
Q4 2024

Feb 12, 2025
BUY
$3.18 - $4.46 $705,657 - $989,696
221,905 Added 68.3%
546,807 $1.78 Million
Q3 2024

Dec 26, 2024
SELL
$3.0 - $5.55 $466,077 - $862,242
-155,359 Reduced 32.35%
324,902 $1.07 Million
Q3 2024

Nov 08, 2024
SELL
$3.0 - $5.55 $466,077 - $862,242
-155,359 Reduced 32.35%
324,902 $1.07 Million
Q2 2024

Dec 26, 2024
BUY
$3.31 - $18.51 $514,238 - $2.88 Million
155,359 Added 47.82%
480,261 $2.04 Million
Q2 2024

Aug 12, 2024
SELL
$3.31 - $18.51 $1.82 Million - $10.2 Million
-548,788 Reduced 53.33%
480,261 $2.04 Million
Q1 2024

Dec 26, 2024
BUY
$9.77 - $21.47 $6.88 Million - $15.1 Million
704,147 Added 216.73%
1,029,049 $15.1 Million
Q1 2024

May 10, 2024
SELL
$9.77 - $21.47 $1.03 Million - $2.27 Million
-105,695 Reduced 9.31%
1,029,049 $15.1 Million
Q4 2023

Dec 26, 2024
BUY
$4.48 - $10.11 $3.63 Million - $8.19 Million
809,842 Added 249.26%
1,134,744 $10.9 Million
Q4 2023

Feb 12, 2024
BUY
$4.48 - $10.11 $377,099 - $850,999
84,174 Added 8.01%
1,134,744 $10.9 Million
Q3 2023

Nov 14, 2023
SELL
$4.48 - $6.19 $893,410 - $1.23 Million
-199,422 Reduced 15.95%
1,050,570 $4.9 Million
Q2 2023

Aug 11, 2023
BUY
$4.62 - $7.54 $4.84 Million - $7.9 Million
1,047,650 Added 517.76%
1,249,992 $6.69 Million
Q1 2023

May 18, 2023
BUY
$4.82 - $7.24 $222,577 - $334,328
46,178 Added 29.57%
202,342 $1.45 Million
Q1 2023

May 11, 2023
SELL
$4.82 - $7.24 $385,277 - $578,714
-79,933 Reduced 33.86%
156,164 $1.12 Million
Q4 2022

Feb 13, 2023
SELL
$3.34 - $6.98 $311,819 - $651,645
-93,359 Reduced 28.34%
236,097 $1.58 Million
Q3 2022

Nov 14, 2022
SELL
$3.01 - $5.22 $209,489 - $363,301
-69,598 Reduced 17.44%
329,456 $1.14 Million
Q2 2022

Aug 11, 2022
BUY
$2.25 - $9.99 $259,411 - $1.15 Million
115,294 Added 40.63%
399,054 $1.18 Million
Q1 2022

May 11, 2022
BUY
$8.12 - $16.9 $1.52 Million - $3.17 Million
187,724 Added 195.47%
283,760 $2.5 Million
Q4 2021

Feb 10, 2022
SELL
$15.91 - $21.88 $74,633 - $102,639
-4,691 Reduced 4.66%
96,036 $1.54 Million
Q3 2021

Nov 12, 2021
BUY
$19.74 - $28.7 $1.99 Million - $2.89 Million
100,727 New
100,727 $2.11 Million

Others Institutions Holding MGNX

# of Institutions
119
Shares Held
52.3M
Call Options Held
55.3K
Put Options Held
35.9K
View Full List

About MACROGENICS INC

MGNX Quotes by TradingView
  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $97.1M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email